Dopamine Agonist-Induced Impulse Control Disorders in Patients with Prolactinoma: A Cross-Sectional Multicenter Study

Simple item page
dc.contributor.authorDogansen S.C.
dc.contributor.authorCikrikcili U.
dc.contributor.authorOruk G.
dc.contributor.authorKutbay N.O.
dc.contributor.authorTanrikulu S.
dc.contributor.authorHekimsoy Z.
dc.contributor.authorHadzalic A.
dc.contributor.authorGorar S.
dc.contributor.authorOmma T.
dc.contributor.authorMert M.
dc.contributor.authorAkbaba G.
dc.contributor.authorYalin G.Y.
dc.contributor.authorBayram F.
dc.contributor.authorOzkan M.
dc.contributor.authorYarman S.
dc.date.accessioned2024-07-22T08:08:43Z
dc.date.available2024-07-22T08:08:43Z
dc.date.issued2019
dc.description.abstractDopamine agonist (DA)-induced impulse control disorder (ICD) in patients with prolactinomas is not sufficiently known. Objective: To evaluate the prevalence of DA-induced ICDs and possible risk factors related to these disorders in patients with prolactinoma. Design, Setting, and Participants: This is a cross-sectional multicenter study involving 308 patientswith prolactinoma followed up in tertiary referral centers who received at least three months of DA therapy. DA-induced ICDs (pathological gambling, hypersexuality, compulsive shopping, and compulsive eating) and impulsivity were assessed using the Questionnaire for Impulsive- Compulsive Disorders in Parkinson Disease and the Barratt Impulsiveness Scale-11, respectively. Patients were evaluated in terms of parameters related to ICD development. © 2019 Endocrine Society.
dc.identifier.DOI-ID10.1210/jc.2018-02202
dc.identifier.issn0021972X
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/14505
dc.language.isoEnglish
dc.publisherEndocrine Society
dc.rightsAll Open Access; Bronze Open Access
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectCross-Sectional Studies
dc.subjectDisruptive, Impulse Control, and Conduct Disorders
dc.subjectDopamine Agonists
dc.subjectFemale
dc.subjectFollow-Up Studies
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPituitary Neoplasms
dc.subjectPrevalence
dc.subjectProlactinoma
dc.subjectPsychiatric Status Rating Scales
dc.subjectRisk Factors
dc.subjectSurveys and Questionnaires
dc.subjectYoung Adult
dc.subjectbromocriptine
dc.subjectcabergoline
dc.subjecttestosterone
dc.subjectdopamine receptor stimulating agent
dc.subjectadolescent
dc.subjectadult
dc.subjectaged
dc.subjectalcohol consumption
dc.subjectArticle
dc.subjectattention
dc.subjectawareness
dc.subjectBarratt Impulsiveness Scale
dc.subjectclinical effectiveness
dc.subjectclinical evaluation
dc.subjectcompulsive buying
dc.subjectcross-sectional study
dc.subjectdisease association
dc.subjectdrug efficacy
dc.subjectfemale
dc.subjectfollow up
dc.subjectfood addiction
dc.subjecthuman
dc.subjecthypersexuality
dc.subjectimpulsiveness
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmulticenter study
dc.subjectParkinson disease
dc.subjectpathological gambling
dc.subjectprevalence
dc.subjectpriority journal
dc.subjectprolactinoma
dc.subjectrisk assessment
dc.subjectrisk factor
dc.subjectsmoking
dc.subjecttertiary care center
dc.subjecttestosterone blood level
dc.subjectclinical trial
dc.subjecthypophysis tumor
dc.subjectimpulse control disorder
dc.subjectmiddle aged
dc.subjectprolactinoma
dc.subjectpsychological rating scale
dc.subjectquestionnaire
dc.subjectyoung adult
dc.titleDopamine Agonist-Induced Impulse Control Disorders in Patients with Prolactinoma: A Cross-Sectional Multicenter Study
dc.typeArticle

Files

Collections

Scopus Koleksiyonu